Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

ConditionIBS - Irritable Bowel Syndrome

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age18+

SponsorTanta University

About this trial

Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

• Age ≥ 18 years,

Man and Women, Negative pregnancy test and effective contraception,

IBS defined by the Rome criteria IV

During the previous seven days the inclusion visit, average numeric rating scale (NRS) pain ≥ 4.

Disqualifiers

• Breastfeeding

Diabetic patients

Significant liver function abnormalities (transaminases> 3N, cholestasis) and moderate renal disease (MDRD <60 ml / min)

Addiction to alcohol and / or drugs,

Trial design

Design model

Parallel

Treatments tested in this trial

pentoxyifylline
Drug
Pentoxyifylline two times daily for 3 months
Mebeverine
Drug
Mebeverine 3 times for 3 months
ethosuximide
Drug
ethosuximide 3 times for 3 months

Treatment groups

60 Participants

are divided into 3 treatment groups

Group A: MebeverineActive comparator 1 intervention

Group B: EthosuximideExperimental treatment 1 intervention

Group C: PentoxyifyllineExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Number of patients with improved Visual analog scales (VAS) for assessment of pain in IBS

the number of patients with improved Visual analog scales (VAS) for assessment of pain in IBS

Time frame

6 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tanta University

Lead sponsor

Source ClinicalTrials.gov

Apply now